<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Oxybutynin: Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Oxybutynin: Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Oxybutynin: Pediatric drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_general" data-topicid="9728" href="/d/html/9728.html" rel="external">see "Oxybutynin: Drug information"</a> and <a class="drug drug_patient" data-topicid="10938" href="/d/html/10938.html" rel="external">see "Oxybutynin: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F204694"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Ditropan XL [DSC];</li>
<li>Gelnique;</li>
<li>Oxytrol;</li>
<li>Oxytrol For Women [OTC]</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52867788"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>APO-Oxybutynin;</li>
<li>Ditropan XL [DSC];</li>
<li>Oxytrol [DSC];</li>
<li>PMS-Oxybutynin;</li>
<li>RIVA-Oxybutynin;</li>
<li>TEVA-Oxybutynin</li></ul></div>
<div class="list_set htclist drugH1Div drugBrandNames" id="F1060756"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Antispasmodic Agent, Urinary</span></li></ul></div>
<div class="block dop drugH1Div" id="F204716"><span class="drugH1">Dosing: Pediatric</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="96343355-4cab-4db1-962f-6ff429285013">Neurogenic/overactive bladder</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Neurogenic/overactive bladder: </b></p>
<p style="text-indent:-2em;margin-left:4em;">Oral:</p>
<p style="text-indent:-2em;margin-left:6em;">Immediate release:</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Weight-directed dosing: </i></p>
<p style="text-indent:-2em;margin-left:10em;">Infants, Children, and Adolescents: Limited data available: Oral: 0.1 to 0.6 mg/kg/day in 2 to 4 divided doses; most commonly divided in 3 doses; maximum dose: 5 mg/dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-9720583','lexi-content-ref-34176749','lexi-content-ref-31724222','lexi-content-ref-11350411','lexi-content-ref-28712052','lexi-content-ref-32115375','lexi-content-ref-22532368']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-9720583','lexi-content-ref-34176749','lexi-content-ref-31724222','lexi-content-ref-11350411','lexi-content-ref-28712052','lexi-content-ref-32115375','lexi-content-ref-22532368'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Fixed dosing: </i></p>
<p style="text-indent:-2em;margin-left:10em;">Children &gt;5 years and Adolescents: Oral: Initial: 5 mg twice daily; increase as necessary up to 5 mg 3 times daily; adult maximum dose: 5 mg 4 times daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Extended release:</p>
<p style="text-indent:-2em;margin-left:8em;">Children ≥6 years and Adolescents: Oral: Initial: 5 mg once daily; adjust dose as needed in 5 mg increments at weekly intervals; maximum daily dose: 20 mg/<b>day</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Intravesical: Limited data available:</p>
<p style="text-indent:-2em;margin-left:6em;">Infants, Children, and Adolescents: Intravesical: 0.1 to 0.9 mg/kg/day in 2 to 3 divided doses (higher daily doses are usually administered in 3 divided doses); maximum dose: 5 mg/dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-9883225','lexi-content-ref-9719281','lexi-content-ref-9720583','lexi-content-ref-31724222','lexi-content-ref-11350411','lexi-content-ref-10822396','lexi-content-ref-22532368','lexi-content-ref-31117096']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-9883225','lexi-content-ref-9719281','lexi-content-ref-9720583','lexi-content-ref-31724222','lexi-content-ref-11350411','lexi-content-ref-10822396','lexi-content-ref-22532368','lexi-content-ref-31117096'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Transdermal: Limited data available:</p>
<p style="text-indent:-2em;margin-left:6em;">Children ≥4 years and Adolescents: Transdermal: Apply one 3.9 mg/day patch twice weekly (every 3 to 4 days); dosing based on 2 small pediatric studies (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19683731','lexi-content-ref-24477421','lexi-content-ref-22532368']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19683731','lexi-content-ref-24477421','lexi-content-ref-22532368'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="e9e947ac-479c-4aa9-b20c-cd1e8a7dc25d">Nocturnal enuresis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Nocturnal enuresis:</b> Limited data available: Children ≥6 years and Adolescents: Immediate release: Oral: Initial: 5 mg once daily at bedtime; may increase dose by 2.5 mg/dose at 2-week intervals based on patient response to a maximum of 10 mg once daily. Use in combination with desmopressin (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27373215','lexi-content-ref-33931318','lexi-content-ref-32968391']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27373215','lexi-content-ref-33931318','lexi-content-ref-32968391'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="e52912dd-2983-4445-8d7d-632db996bfec">Primary focal hyperhidrosis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Primary focal hyperhidrosis:</b> Limited data available: Children ≥4 years and Adolescents: Immediate release: Oral: Initial: 2.5 mg once daily; increase by 2.5 mg/dose at 1- to 2-week intervals based on patient response and tolerability; usual effective dose range: 5 to 10 mg/day in 1 to 2 divided doses. Maximum reported daily dose: 15 mg/<b>day</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27122197','lexi-content-ref-27029500','lexi-content-ref-23627681','lexi-content-ref-25490865']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27122197','lexi-content-ref-27029500','lexi-content-ref-23627681','lexi-content-ref-25490865'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F51151115"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Altered kidney function:</b> Mild to severe impairment: Infants, Children, and Adolescents: Oral, Transdermal: There are no dosage adjustments provided in the manufacturer's labeling (has not been studied). Dosage adjustment is likely unnecessary, as &lt;0.1% is eliminated unchanged in the urine; however, use with caution due to limited data in patients with altered kidney function (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hemodialysis, intermittent:</b> Unlikely to be dialyzed (highly protein bound).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Peritoneal dialysis:</b> Unlikely to be dialyzed (highly protein bound).</p></div>
<div class="block dohp drugH1Div" id="F51151116"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;">Oral, Transdermal: There are no dosage adjustments provided in the manufacturer’s labeling (has not been studied); use with caution.</p></div>
<div class="block doa drugH1Div" id="F204698"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="9728" href="/d/html/9728.html" rel="external">see "Oxybutynin: Drug information"</a>)</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="e512851c-5f54-40d3-beee-88b90862f34c">Overactive bladder</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Overactive bladder (urinary urgency with or without incontinence) (alternative agent):</b>
<b>Note: </b>Consider use after inadequate response to or in conjunction with nonpharmacologic measures (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Gormley.2019']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Gormley.2019'])">Ref</a></span>). Use of other antimuscarinic agents may be preferred to minimize adverse effects (eg, cognitive deficits) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Gormley.2019','lexi-content-ref-18699842']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Gormley.2019','lexi-content-ref-18699842'])">Ref</a></span>). Full benefit may not be observed until after several weeks of treatment; trial for ≥4 to 12 weeks before considering other options (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Gormley.2019','lexi-content-ref-Lukacz.2019']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Gormley.2019','lexi-content-ref-Lukacz.2019'])">Ref</a></span>). Antimuscarinic agents are <b>not </b>recommended in patients with stress type incontinence (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25222388']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25222388'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note:</b> ER formulations are preferred due to improved tolerability (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Gormley.2019','lexi-content-ref-18439051']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Gormley.2019','lexi-content-ref-18439051'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Extended release:</i> Initial: 5 to 10 mg once daily; adjust dose as needed based on response and tolerability in 5 mg increments every 1 to ≥2 weeks (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Lukacz.2019']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Lukacz.2019'])">Ref</a></span>); maximum dose: 30 mg once daily.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Immediate release</i>: 5 mg 2 to 3 times daily; adjust dose as needed based on response and tolerability in 5 mg increments approximately every 2 weeks (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Lukacz.2019']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Lukacz.2019'])">Ref</a></span>); maximum dose: 5 mg 4 times daily.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Topical gel:</b> Apply contents of 1 sachet (100 mg/g) or 1 actuation of the pump (100 mg/g) once daily.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Transdermal:</b> Apply one 3.9 mg/day patch twice weekly (every 3 to 4 days); change the patch on the same 2 days each week.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>OTC labeling (patient-guided therapy):</i> Females: Apply one 3.9 mg/day patch every 4 days.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="e52912dd-2983-4445-8d7d-632db996bfec">Primary focal hyperhidrosis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Primary focal hyperhidrosis (alternative agent) (off-label use): </b>
<b>Oral:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Extended release:</i> 5 to 10 mg once daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Smith.2020']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Smith.2020'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Immediate release:</i> Initial: 2.5 mg once daily; gradually titrate as needed and tolerated; usual effective dose range: 5 to 10 mg/day in 2 divided doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26114588','lexi-content-ref-Smith.2020','lexi-content-ref-22341836']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26114588','lexi-content-ref-Smith.2020','lexi-content-ref-22341836'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50990703"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">The renal dosing recommendations are based upon the best available evidence and clinical expertise. Senior Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Oral, topical, transdermal: </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Altered kidney function: </b>Mild to severe impairment: No dosage adjustment necessary (&lt;0.1% of drug and its active metabolite eliminated in urine) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>); however, use with caution due to limited data in patients with altered kidney function (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Hemodialysis, intermittent (thrice weekly):</b> Unlikely to be dialyzed (highly protein bound): No supplemental dose or dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>); use with caution.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Peritoneal dialysis:</b> Unlikely to be dialyzed (highly protein bound): No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>); use with caution.</p></div>
<div class="block doha drugH1Div" id="F50988039"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling (has not been studied); use with caution.</p></div>
<div class="block arsc drugH1Div" id="F54883801"><span class="drugH1">Adverse Reactions (Significant): Considerations</span>
<div class="collapsible">
<span class="collapsible-title">Anticholinergic effects</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Anticholinergic agents, including oxybutynin, may cause reversible, dose-dependent antimuscarinic adverse effects, including, but not limited to, CNS effects (<b>agitation</b>, <b>confusion</b>, cognitive impairment,<b> drowsiness</b>, <b>dizziness</b>, <b>hallucinations</b>, <b>headache</b>), GU effects (eg, <b>urinary retention</b>), GI effects (eg, gastric retention,<b> decreased </b>
<b>gastrointestinal motility</b>, <b>constipation</b>, <b>xerostomia</b>) ophthalmic effects (eg, <b>blurred vision, mydriasis</b>, <b>xerophthalmia</b>), cardiovascular effects (eg, <b>tachycardia</b>), and dermatologic effects (eg, <b>hypohidrosis</b>, <b>xeroderma</b>) in adult and pediatric patients (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11394733','lexi-content-ref-22070184','lexi-content-ref-15970828','lexi-content-ref-16469019','lexi-content-ref-11350411','lexi-content-ref-18786150','lexi-content-ref-30087808','lexi-content-ref-20596778','lexi-content-ref-Nelson.2019','lexi-content-ref-16483863','lexi-content-ref-37160401','lexi-content-ref-23332882']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11394733','lexi-content-ref-22070184','lexi-content-ref-15970828','lexi-content-ref-16469019','lexi-content-ref-11350411','lexi-content-ref-18786150','lexi-content-ref-30087808','lexi-content-ref-20596778','lexi-content-ref-Nelson.2019','lexi-content-ref-16483863','lexi-content-ref-37160401','lexi-content-ref-23332882'])">Ref</a></span>). Exertional heat illness (risk factor anticholinergic-induced hypohidrosis) may occur, especially when patients exert themselves under high environmental temperatures/humidity. Xerostomia is the most frequent adverse reaction causing discontinuation of therapy.</p>
<p style="text-indent:-2em;margin-left:2em;">When compared to other medications used for the treatment of overactive bladder (eg, anticholinergic agents, beta<sub>3</sub> agonists), oxybutynin has been associated with a higher risk of affect/<b>mood disorders</b>, agitation, and balance/<b>movement disorders</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-35536677']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-35536677'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Dose-related; an extension of antimuscarinic pharmacological properties.</p>
<p style="text-indent:-2em;margin-left:6em;">Of note, an active metabolite, desethyloxybutynin, has pharmacological activity similar to that of oxybutynin; therefore, a route of administration which bypasses hepatic metabolism to desethyloxybutynin (eg, transdermal) may result in less antimuscarinic activity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11435842']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11435842'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Varied; timing may be impacted by high doses, dose titration, or accumulation.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Conditions which may lead to accumulation (eg, older patients (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-35587029']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-35587029'])">Ref</a></span>), patients with hepatic or renal impairment)</p>
<p style="text-indent:-2em;margin-left:6em;">• Routes of administration that lead to higher serum concentrations (eg, immediate release oral formulations, intravesical administration) or higher concentrations of active metabolite (eg, oral formulations) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17333521','lexi-content-ref-9720583','lexi-content-ref-11394733','lexi-content-ref-11435842','lexi-content-ref-11350411','lexi-content-ref-18639290']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17333521','lexi-content-ref-9720583','lexi-content-ref-11394733','lexi-content-ref-11435842','lexi-content-ref-11350411','lexi-content-ref-18639290'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">• Preexisting decreased GI motility or GI obstructive disorders. In patients with ulcerative colitis, use may decrease gastric motility to the point of increasing the risk of paralytic ileus or toxic megacolon.</p>
<p style="text-indent:-2em;margin-left:6em;">• Preexisting angle-closure glaucoma (use is contraindicated with uncontrolled narrow-angle glaucoma)</p>
<p style="text-indent:-2em;margin-left:6em;">• Preexisting coronary artery disease, heart failure, hypertension, and/or cardiac arrhythmias</p>
<p style="text-indent:-2em;margin-left:6em;">• Physical exertion in high ambient temperature and humidity may lead to exertional heat illness</p></div>
</div>
</div>
<div class="block adr drugH1Div" id="F204660"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. As reported with oral administration, unless otherwise noted.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Constipation (oral: 9% to 15%; transdermal: 3%; topical gel: 1%)<span class="lexi-table-link-container"> (<a aria-label="Constipation table link" class="lexi-table-link" data-table-id="lexi-content-constipation" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-constipation')">table 1</a>)</span><span class="table-link" style="display:none;">Constipation</span>, nausea (5% to 12%), xerostomia (oral: 35% to 72%; topical gel, transdermal: 4% to 10%)<span class="lexi-table-link-container"> (<a aria-label="Xerostomia table link" class="lexi-table-link" data-table-id="lexi-content-xerostomia" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-xerostomia')">table 2</a>)</span><span class="table-link" style="display:none;">Xerostomia</span></p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Constipation" frame="border" id="lexi-content-constipation" rules="all">
<caption style="text-align:center;">
<b>Oxybutynin: Adverse Reaction: Constipation</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Oxybutynin)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Dosage Form</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Oxybutynin)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">3%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">0%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Oxytrol (3.9 mg/day)</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Transdermal</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">121</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">117</p></td></tr></tbody></table>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Xerostomia" frame="border" id="lexi-content-xerostomia" rules="all">
<caption style="text-align:center;">
<b>Oxybutynin: Adverse Reaction: Xerostomia</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Oxybutynin)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Dosage Form</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Oxybutynin)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">10%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">8%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Oxytrol (3.9 mg/day)</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Transdermal</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">125</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">132</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">8%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">3%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Gelnique (1 g/day)</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Gel</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">389</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">400</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">4%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Oxytrol (3.9 mg/day)</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Transdermal</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">121</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">117</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">Local: Application-site pruritus (transdermal: 14% to 17%; topical gel: 2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Dizziness (oral: 5% to 17%; topical gel: 3%)<span class="lexi-table-link-container"> (<a aria-label="Dizziness table link" class="lexi-table-link" data-table-id="lexi-content-dizziness" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-dizziness')">table 3</a>)</span><span class="table-link" style="display:none;">Dizziness</span>, drowsiness (6% to 14%)</p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Dizziness" frame="border" id="lexi-content-dizziness" rules="all">
<caption style="text-align:center;">
<b>Oxybutynin: Adverse Reaction: Dizziness</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Oxybutynin)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Dosage Form</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Oxybutynin)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">3%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">1%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Gelnique (1 g/day)</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Gel</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">389</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">400</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Decreased blood pressure (1% to 5%), edema (1% to 5%), flushing (1% to 5%), increased blood pressure (1% to 5%), palpitations (1% to 5%), peripheral edema (1% to 5%), sinoatrial nodal rhythm disorder (1% to 5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Macular eruption (transdermal: 3%; application site), pruritus (oral, topical gel: 1% to 2%), xeroderma (2% to 3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Fluid retention (&lt;5%), increased serum glucose (1% to 5%), increased thirst (≤5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal pain (2%), coated tongue (1% to 5%), diarrhea (3% to 8%), dysgeusia (2%), dyspepsia (5% to 6%), eructation (1% to 5%), flatulence (1% to 3%), gastroesophageal reflux disease (≤1%), upper abdominal pain (1% to 5%), viral gastroenteritis (topical gel: 2%), vomiting (1% to 2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Cystitis (1% to 5%), dysuria (oral, transdermal: 2%), increased post-void residual urine volume (2% to 4%), pollakiuria (1% to 5%), urinary hesitancy (2% to 9%), urinary retention (1% to 6%), urinary tract infection (oral, topical gel: 7%)</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: Fungal infection (1% to 5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Local: Application-site dermatitis (topical gel: 2%), application-site erythema (transdermal: 6% to 8%), application-site rash (transdermal: 3%), application-site reaction (topical gel: 5%), application-site vesicles (transdermal: 3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Asthenia (1% to 5%), confusion (1% to 5%), falling (1% to 5%), fatigue (oral, topical gel: 2% to 3%), headache (oral: 8%; topical gel: 2%), insomnia (3% to 6%), nervousness (7%), pain (1% to 5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Arthralgia (1% to 5%), back pain (1% to 5%), limb pain (1% to 5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Blurred vision (4% to 10%), dry eye syndrome (3%), eye irritation (1% to 5%), visual disturbance (transdermal: 3%)<span class="lexi-table-link-container"> (<a aria-label="Visual disturbance table link" class="lexi-table-link" data-table-id="lexi-content-visual-disturbance" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-visual-disturbance')">table 4</a>)</span><span class="table-link" style="display:none;">Visual disturbance</span></p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Visual disturbance" frame="border" id="lexi-content-visual-disturbance" rules="all">
<caption style="text-align:center;">
<b>Oxybutynin: Adverse Reaction: Visual disturbance</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Oxybutynin)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Dosage Form</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Oxybutynin)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">3%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">0%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Oxytrol (3.9 mg/day)</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Transdermal</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">121</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">117</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">Renal: Flank pain (1% to 5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Asthma (1% to 5%), bronchitis (1% to 5%), cough (2% to 3%), dry nose (2% to 5%), dry throat (2% to 3%), hoarseness (1% to 5%), nasal congestion (1% to 5%), nasopharyngitis (oral, topical gel: 1% to 5%), oropharyngeal pain (2%), paranasal sinus congestion (1% to 5%), pharyngolaryngeal pain (1% to 5%), sinus headache (1% to 5%), upper respiratory tract infection (oral, topical gel: 1% to 5%)</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Chest discomfort</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Hot flash</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Anorexia, dysphagia</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Voice disorder</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Cardiac arrhythmia (Ciftci 2013), hypertension (Armstrong 2007; Branson 2008), prolonged QT interval on ECG (Ciftci 2013; Hussain 1996), tachycardia</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Fixed drug eruption (lip) (Pemberton 2008), hypohidrosis (Ghaleiha 2012)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Heatstroke (Adubofour 1996)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Decreased gastrointestinal motility (Meek 2011)</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Increased liver enzymes (Alrawashdeh 2018)</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Anaphylaxis, angioedema</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Agitation (Lackner 2008), balance impairment (Sze 2022), delirium (Götz 2009), delusion (Sze 2022), hallucination (Götz 2009; Gulsun 2006), hypertonia (Chu 2005), memory impairment (Nye 2010), mood disorder (Sze 2022), movement disorder (Sze 2022), paresthesia (Sze 2022), psychotic reaction (Gulsun 2006), seizure (Branson 2008)</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Glaucoma (Haddad 2018, Jain 2015), mydriasis</p></div>
<div class="block coi drugH1Div" id="F204675"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Hypersensitivity to oxybutynin or any component of the formulation; patients with or at risk for uncontrolled narrow-angle glaucoma, urinary retention, gastric retention or conditions with severely decreased GI motility.</p>
<p style="text-indent:-2em;margin-left:2em;">OTC labeling: When used for self-medication, do not use if you have pain or burning when urinating, blood in urine, unexplained lower back or side pain, cloudy or foul-smelling urine; in males; age &lt;18 years; only experience accidental urine loss when cough, sneeze, or laugh; diagnosis of urinary or gastric retention; glaucoma; hypersensitivity to oxybutynin.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Canadian labeling:</i> Additional contraindications (not in US labeling): Transdermal: Myasthenia gravis.</p></div>
<div class="block war drugH1Div" id="F204657"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Exertional heat illness: May increase the risk of this illness with intense exertion in the heat.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Dementia: Use with caution in patients with dementia treated with cholinesterase inhibitors; may aggravate symptoms of disease.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic impairment: Use with caution in patients with hepatic impairment (limited experience).</p>
<p style="text-indent:-2em;margin-left:4em;">• Hiatal hernia: Use with caution in patients with hiatal hernia.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hyperthyroidism: Use with caution in patients with hyperthyroidism; may exacerbate condition.</p>
<p style="text-indent:-2em;margin-left:4em;">• Myasthenia gravis: Avoid use in patients with myasthenia gravis; may exacerbate condition. Discontinue therapy if signs/symptoms occur.</p>
<p style="text-indent:-2em;margin-left:4em;">• Parkinson disease: Use with caution in patients with Parkinson disease; may aggravate symptoms of disease.</p>
<p style="text-indent:-2em;margin-left:4em;">• Renal impairment: Use with caution in patients with renal impairment (limited experience).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Dosage form specific issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• ER formulation: The ER formulation consists of drug within a nondeformable matrix; following drug release/absorption, the matrix/shell is expelled in the stool. The use of nondeformable products in patients with known stricture/narrowing of the GI tract has been associated with symptoms of obstruction (rare).</p>
<p style="text-indent:-2em;margin-left:4em;">• Topical gel: To minimize transferring medication to others, cover treatment area with clothing after gel has dried. Discontinue use if skin irritation occurs. Contains ethanol; do not expose to open flame or smoking until gel has dried.</p>
<p style="text-indent:-2em;margin-left:4em;">• Transdermal patch: May contain conducting metal (eg, aluminum); remove patch prior to MRI.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• OTC labeling: Other causes of frequent urination (UTI, diabetes, early pregnancy, other serious conditions) may need to be considered prior to use. Patients should contact a health care provider if symptoms do not improve within 2 weeks of initial use or for new or worsening symptoms.</p></div>
<div class="block add-pediatric-warn-info drugH1Div" id="F52878572"><span class="drugH1">Warnings: Additional Pediatric Considerations</span>
<p style="text-indent:0em;display:inline">Some dosage forms may contain propylene glycol; in neonates, large amounts of propylene glycol delivered orally, intravenously (eg, &gt;3,000 mg/day), or topically have been associated with potentially fatal toxicities which can include metabolic acidosis, seizures, renal failure, and CNS depression; toxicities have also been reported in children and adults including hyperosmolality, lactic acidosis, seizures, and respiratory depression; use caution (AAP 1997; Shehab 2009).</p></div>
<div class="block prod-avail drugH1Div" id="F55463717"><span class="drugH1">Product Availability</span>
<p style="text-indent:0em;display:inline">Gelnique Pump has been discontinued in the United States for &gt;1 year.</p></div>
<div class="block foc drugH1Div" id="F204669"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Gel, Transdermal, as chloride: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Gelnique: 10% (1 g) [contains alcohol, usp]</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Patch Twice Weekly, Transdermal: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Oxytrol: 3.9 mg/24 hr (1 ea, 8 ea)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Oxytrol For Women: 3.9 mg/24 hr (1 ea, 4 ea, 8 ea)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Oral, as chloride: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 5 mg/5 mL (473 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral, as chloride: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 2.5 mg, 5 mg</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet Extended Release 24 Hour, Oral, as chloride: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Ditropan XL: 5 mg [DSC], 10 mg [DSC]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 5 mg, 10 mg, 15 mg</p></div>
<div class="block geq drugH1Div" id="F204653"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">May be product dependent</p></div>
<div class="block fee drugH1Div" id="F204676"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Gel</b> (Gelnique Transdermal)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">10% (per gram): $15.82</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Patch, twice-weekly</b> (Oxytrol For Women Transdermal)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">3.9 mg/24 hrs (per each): $3.30</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Patch, twice-weekly</b> (Oxytrol Transdermal)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">3.9 mg/24 hrs (per each): $101.98</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (oxyBUTYnin Chloride Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">5 mg/5 mL (per mL): $0.11 - $1.27</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablet, 24-hour</b> (oxyBUTYnin Chloride ER Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">5 mg (per each): $1.86 - $6.24</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">10 mg (per each): $1.99 - $6.24</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">15 mg (per each): $2.39 - $6.40</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (oxyBUTYnin Chloride Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">2.5 mg (per each): $2.80</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">5 mg (per each): $0.44 - $0.76</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52867789"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Patch Twice Weekly, Transdermal: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Oxytrol: 3.9 mg/24 hr ([DSC])</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Oral, as chloride: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 5 mg/5 mL (473 mL, 500 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral, as chloride: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 2.5 mg, 5 mg</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet Extended Release 24 Hour, Oral, as chloride: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Ditropan XL: 5 mg [DSC], 10 mg [DSC] [contains polysorbate 80]</p></div>
<div class="block admp drugH1Div" id="F52613490"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Oral: May be administered with or without food. Extended-release tablets must be swallowed whole with liquid; do not chew, divide, or crush; take at approximately the same time each day.</p>
<p style="text-indent:-2em;margin-left:2em;">Intravesical: Immediately prior to administration, crush the appropriate number of immediate-release tablets based on dose and dissolve in sterile water or saline to a final concentration of 5 mg/mL (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20428289']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20428289'])">Ref</a></span>); after emptying bladder, administer directly into the bladder via catheter (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-9719281','lexi-content-ref-9720583']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-9719281','lexi-content-ref-9720583'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">Transdermal: Apply to clean, dry, smooth (fold-free) intact skin on abdomen, hip, or buttock; do not apply to areas treated with oils, lotions, or powders. Do not apply to areas with cuts, scrapes, or other irritation (ie, rashes). Do not cut the patch. Rotate site of application with each administration and avoid application to the same site within 7 days. Wear patch under clothing; do not expose to sunlight.</p></div>
<div class="block adm drugH1Div" id="F204672"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Oral:</b> ER tablets: Administer without regard to meals. Must be swallowed whole with liquid; do not crush, divide, or chew; take at approximately the same time each day.</p>
<p style="text-indent:-2em;margin-left:4em;">Bariatric surgery: Some institutions may have specific protocols that conflict with these recommendations; refer to institutional protocols as appropriate. Oral solution, IR tablet, topical gel, and transdermal patch formulations are available. If safety and efficacy can be effectively monitored, no change in formulation or administration is required after bariatric surgery.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Topical gel:</b> For topical use only. Apply to clean, dry, intact skin on abdomen, thighs, or upper arms/shoulders. Rotate application sites; do not apply to the same site on consecutive days. Wash hands after use. Cover treated area with clothing after gel has dried to prevent transfer of medication to others. Do not bathe, shower, or swim until 1 hour after gel applied. Do not apply to recently shaved skin.</p>
<p style="text-indent:-2em;margin-left:4em;">Pump: Prior to initial use, prime pump several times (≥ 4 times) until gel begins to come out; after gel is observed, fully depress the pump one more time and discard gel dispensed from pump during priming. One full depression of the pump provides one dose; discard after 30 doses.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Transdermal:</b> Apply to clean, dry, smooth (fold-free) skin on abdomen, hip, or buttock; do not apply to areas treated with oils, lotions, or powders. Do not apply to areas with cuts, scrapes, or other irritation (ie, rashes). Do not cut the patch. Apply each system at a new site (avoid reapplication to same site within 7 days). Contact with water while bathing, swimming, showering, or exercising will not change the effect; however, rubbing of the patch area should be avoided during these activities. Patch should be worn under clothing; do not expose to sunlight.</p></div>
<div class="block sts drugH1Div" id="F204689"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:-2em;margin-left:2em;">Immediate release tablet and syrup: Store at 20°C to 25°C (68°F to 77°F). Protect from light.</p>
<p style="text-indent:-2em;margin-left:2em;">Extended release tablet: Store at 25°C (77°F); excursions permitted to 15°C to 30°C (59°F to 86°F). Protect from moisture and humidity.</p>
<p style="text-indent:-2em;margin-left:2em;">Topical gel: Store at 20°C to 25°C (68°C to 77°F). Protect from moisture and humidity. Keep away from open flame. Do not store outside the sealed pouch or pump dispenser; apply immediately after removal from the protective pouch or once contents expelled from pump dispenser. Discard used sachets such that accidental application or ingestion by children, pets, or others are avoided.</p>
<p style="text-indent:-2em;margin-left:2em;">Transdermal patch: Store at 20°C to 25°C (68°F to 77°F). Protect from moisture and humidity. Do not store outside the sealed pouch; apply immediately after removal from the protective pouch. Discard used patches such that accidental application or ingestion by children, pets, or others is avoided.</p></div>
<div class="block usep drugH1Div" id="F53568146"><span class="drugH1">Use</span>
<p style="text-indent:-2em;margin-left:2em;">Oral:</p>
<p style="text-indent:-2em;margin-left:4em;">Immediate-release tablets, oral solution: Relief of symptoms of bladder instability associated with voiding in patients with uninhibited or reflex neurogenic bladder (ie, urgency, frequency, urinary leakage, urge incontinence, dysuria) (FDA approved in ages &gt;5 years and adults); has also been used for treatment of primary focal hyperhidrosis and nocturnal enuresis.</p>
<p style="text-indent:-2em;margin-left:4em;">Extended-release tablets: Treatment of symptoms of detrusor overactivity associated with a neurological condition (FDA approved in pediatric patients ages ≥6 years); treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and frequency (FDA approved in adults).</p>
<p style="text-indent:-2em;margin-left:2em;">Topical:</p>
<p style="text-indent:-2em;margin-left:4em;">Topical gel (Gelnique): Treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and frequency (FDA approved in adults).</p>
<p style="text-indent:-2em;margin-left:4em;">Transdermal patch: Treatment of overactive bladder (Oxytrol: FDA approved in adults).</p></div>
<div class="block mst drugH1Div" id="F204742"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">OxyBUTYnin may be confused with oxyCODONE, OxyCONTIN, oxyMORphone</p>
<p style="text-indent:-2em;margin-left:4em;">Ditropan may be confused with Detrol, diazePAM, Diprivan, dithranol</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Older Adult: High-Risk Medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Beers Criteria: Oxybutynin is identified in the Beers Criteria as a potentially inappropriate medication in patients 65 years and older due to its strong anticholinergic properties (Beers Criteria [AGS 2023]).</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Other safety concerns:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Transdermal patch may contain conducting metal (eg, aluminum); remove patch prior to MRI.</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F204730"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of CYP3A4 (minor); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>
<div class="block dri drugH1Div" id="F204662"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Acetylcholinesterase Inhibitors: May diminish the therapeutic effect of Anticholinergic Agents. Anticholinergic Agents may diminish the therapeutic effect of Acetylcholinesterase Inhibitors.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Aclidinium: May enhance the anticholinergic effect of Anticholinergic Agents.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Alcohol (Ethyl): May enhance the CNS depressant effect of OxyBUTYnin.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amantadine: May enhance the anticholinergic effect of Anticholinergic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Anticholinergic Agents: May enhance the adverse/toxic effect of other Anticholinergic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Botulinum Toxin-Containing Products: May enhance the anticholinergic effect of Anticholinergic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cannabinoid-Containing Products: Anticholinergic Agents may enhance the tachycardic effect of Cannabinoid-Containing Products. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chloral Betaine: May enhance the adverse/toxic effect of Anticholinergic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chlorprothixene: Anticholinergic Agents may enhance the anticholinergic effect of Chlorprothixene. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cimetropium: Anticholinergic Agents may enhance the anticholinergic effect of Cimetropium. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">CloZAPine: Anticholinergic Agents may enhance the constipating effect of CloZAPine.  Management: Consider alternatives to this combination whenever possible. If combined, monitor closely for signs and symptoms of gastrointestinal hypomotility and consider prophylactic laxative treatment.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inhibitors (Strong): May increase the serum concentration of OxyBUTYnin.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Eluxadoline: Anticholinergic Agents may enhance the constipating effect of Eluxadoline. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Erythromycin (Systemic): May increase the serum concentration of OxyBUTYnin.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Gastrointestinal Agents (Prokinetic): Anticholinergic Agents may diminish the therapeutic effect of Gastrointestinal Agents (Prokinetic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Glucagon: Anticholinergic Agents may enhance the adverse/toxic effect of Glucagon. Specifically, the risk of gastrointestinal adverse effects may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Glycopyrrolate (Oral Inhalation): Anticholinergic Agents may enhance the anticholinergic effect of Glycopyrrolate (Oral Inhalation). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Glycopyrronium (Topical): May enhance the anticholinergic effect of Anticholinergic Agents.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ipratropium (Oral Inhalation): May enhance the anticholinergic effect of Anticholinergic Agents.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Itopride: Anticholinergic Agents may diminish the therapeutic effect of Itopride. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Levosulpiride: Anticholinergic Agents may diminish the therapeutic effect of Levosulpiride. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mianserin: May enhance the anticholinergic effect of Anticholinergic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mirabegron: Anticholinergic Agents may enhance the adverse/toxic effect of Mirabegron. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nitroglycerin: Anticholinergic Agents may decrease the absorption of Nitroglycerin. Specifically, anticholinergic agents may decrease the dissolution of sublingual nitroglycerin tablets, possibly impairing or slowing nitroglycerin absorption. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Opioid Agonists: Anticholinergic Agents may enhance the adverse/toxic effect of Opioid Agonists. Specifically, the risk for constipation and urinary retention may be increased with this combination. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Oxatomide: May enhance the anticholinergic effect of Anticholinergic Agents.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Potassium Chloride: Anticholinergic Agents may enhance the ulcerogenic effect of Potassium Chloride.  Management: Patients on drugs with substantial anticholinergic effects should avoid using any solid oral dosage form of potassium chloride.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Potassium Citrate: Anticholinergic Agents may enhance the ulcerogenic effect of Potassium Citrate.  Management:  Patients on drugs with substantial anticholinergic effects should avoid using any solid oral dosage form of potassium citrate.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pramlintide: May enhance the anticholinergic effect of Anticholinergic Agents. These effects are specific to the GI tract.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ramosetron: Anticholinergic Agents may enhance the constipating effect of Ramosetron. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Revefenacin: Anticholinergic Agents may enhance the anticholinergic effect of Revefenacin. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rivastigmine: Anticholinergic Agents may diminish the therapeutic effect of Rivastigmine. Rivastigmine may diminish the therapeutic effect of Anticholinergic Agents.  Management: Use of rivastigmine with an anticholinergic agent is not recommended unless clinically necessary. If the combination is necessary, monitor for reduced anticholinergic effects.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Secretin: Anticholinergic Agents may diminish the therapeutic effect of Secretin.  Management: Avoid concomitant use of anticholinergic agents and secretin. Discontinue anticholinergic agents at least 5 half-lives prior to administration of secretin.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Thiazide and Thiazide-Like Diuretics: Anticholinergic Agents may increase the serum concentration of Thiazide and Thiazide-Like Diuretics. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tiotropium: Anticholinergic Agents may enhance the anticholinergic effect of Tiotropium. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Topiramate: Anticholinergic Agents may enhance the adverse/toxic effect of Topiramate. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Umeclidinium: May enhance the anticholinergic effect of Anticholinergic Agents.<i> Risk X: Avoid combination</i></p></div>
<div class="block dic drugH1Div" id="F204679"><span class="drugH1">Dietary Considerations</span>
<p style="text-indent:0em;display:inline">Food causes a slight delay in the absorption of the oral solution and bioavailability is increased by ~25%. Absorption of the extended release tablet is not affected by food. May be taken without regard to meals. </p></div>
<div class="block pri drugH1Div" id="F204677"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Adverse events were not observed in animal reproduction studies.</p>
<p style="text-indent:0em;margin-top:2em;">Information related to the use of oxybutynin in pregnant patients treated for neurogenic bladder (Andretta 2019; Beghin 2016) or excessive sweating (Harley 2020) is limited.</p></div>
<div class="block mopp drugH1Div" id="F53751423"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Signs and symptoms of anticholinergic reactions (eg, dry mouth, constipation, dizziness).</p></div>
<div class="block pha drugH1Div" id="F204656"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Direct antispasmodic effect on smooth muscle, also inhibits the action of acetylcholine on smooth muscle (exhibits <sup>1</sup>/<sub>5</sub> the anticholinergic activity of atropine, but has 4-10 times the antispasmodic activity); does not block effects at skeletal muscle or at autonomic ganglia; increases bladder capacity, decreases uninhibited contractions, and delays desire to void, therefore, decreases urgency and frequency</p></div>
<div class="block phk drugH1Div" id="F204674"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Onset of action: Oral: Immediate release: 30 to 60 minutes</p>
<p style="text-indent:-2em;margin-left:4em;">Peak effect: Immediate release: 3 to 6 hours; Extended release: 3 days</p>
<p style="text-indent:-2em;margin-left:2em;">Duration: Oral: Immediate release: 6 to 10 hours; Extended release: Up to 24 hours; Transdermal 96 hours</p>
<p style="text-indent:-2em;margin-left:2em;">Absorption: Oral: Rapid and well absorbed; Transdermal: High</p>
<p style="text-indent:-2em;margin-left:2em;">Distribution: IV: V<sub>d</sub>: 193 L</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: &gt;99% primarily to alpha-1 acid glycoprotein</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Hepatic via CYP3A4; Oral: High first-pass metabolism; forms active and inactive metabolites</p>
<p style="text-indent:-2em;margin-left:2em;">Bioavailability: Oral: Immediate release: 6% (range: 1.6% to 10.9%)</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: IV: ~2 hours (parent drug), 7 to 8 hours (metabolites); Oral: Immediate release: ~2 to 3 hours; Extended release: ~13 hours; Transdermal: 64 hours</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak, serum: Oral: Immediate release: ~60 minutes; Extended release: 4 to 6 hours; Transdermal: 24 to 48 hours</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Urine (&lt;0.1% as metabolites and unchanged drug)</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F204680"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Apo-oxybutynin | Ditropan | Oxybutynin | Pms-oxybutynin</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Delak | Ditropan | Ditropan ud | Oxi Q | Oxibutinina ferring | Oxibutinina Vannier | Oxitina | Oxyurin | Retebem | Retemicon | Soxsup | Urequin</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Detrusan | Ditropan | Oxybutynin | Oxybutynin hexal pharma</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Ditropan | Oxybutynin Sandoz | Oxytrol</span>;</li>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">Uricon</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Ditropan | Driptane | Oxybutynin Ratiopharm | Oxybutynine bexal | Oxybutynine eurogenerics | Oxybutynine hcl merck-generics | Oxybutynine Sandoz</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Cloridrato de Oxibutinina | Dry | Frenurin | Incontinol | Nourin | Retemic | Retemic UD</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Ditropan | Kentera</span>;</li>
<li>
<span class="countryCode">(CI)</span> <span class="country">Côte d'Ivoire</span><span class="countrySeparator">: </span><span class="drugName">Xytinin</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Odranal | Oxiburin | Urazol | Uricont | Urocontinent</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Ao ning | Oxybutynin | Shuang miao | Yi jing</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Delifon | Lyrinel | Mutum | Mutum cr | Oxibutin | Oxibutinina | Sinorin | Uropran</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Ditropan | Kentera | Uroxal</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Cystonorm | Dridase | Kentera | Oxyb | Oxybase | Oxybugamma | Oxybutin | Oxybuton | Oxybutynin | Oxybutynin al | Oxybutynin Billix | Oxybutynin hexal | Oxybutynin Maxmedic | Oxybutynin Ratiopharm | Oxybutyninhydrochlorid Sandoz | Oxymedin | Ryol | Spasyt</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Driptane | Reteven LP | Sutropan | Urginal | Urginal UD</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Mutum</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Cystrin | Driptane</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Detronin | Detrusan | Oxurate | Oxybin | Uripan</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Ditropan | Dresplan | Kentera</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Cystrin | Oksibutin sandoz | Oxybase | Oxybutynin generic | Oxybutynin mylan | Spasmoxyl</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Ditropan | Driptane | Oxybutynine | Oxybutynine accord | Oxybutynine g gam | Oxybutynine merck | Oxybutynine Ratiopharm | Oxybutynine Sandoz | Zatur</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Contimin | Cystrin | Ditropan | Kentera | Lyrinel | Oxybutynin | Oxybutynin Accord | Oxybutynin arrow | Oxybutynin cox | Oxybutynin kent | Oxybutynin Sandoz | Promictuline | Urimin</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Ditropan | Lyrinel | Lyrinel XL</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Apo-Oxybutynine | Pms-oxybutynin</span>;</li>
<li>
<span class="countryCode">(HR)</span> <span class="country">Croatia</span><span class="countrySeparator">: </span><span class="drugName">Driptane</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Ditropan | Huma-oxybutynin | Uroxal</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Cystrin | Ditropan | Kentera | Lyrinel | Oxybutynin | Oxybutynin nicobrand | Renamel</span>;</li>
<li>
<span class="countryCode">(IL)</span> <span class="country">Israel</span><span class="countrySeparator">: </span><span class="drugName">Lyrinel | Novitropan | Oxybutynin GM</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Cystran | Nocturin | Oxybutin | Oxylax | Oxyspas | Tropan</span>;</li>
<li>
<span class="countryCode">(IQ)</span> <span class="country">Iraq</span><span class="countrySeparator">: </span><span class="drugName">Oxybutin</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Ditropan | Kentera | Lyrinel | Ossibutinina | Ossibutinina cloridrato mylan generics | Oxibutinina eg</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Ditropan | Dreptageed</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Brocell | Cobapolas | Delaiv | Delaiv choseido | Esuomin | Fandeheede | Fandeheede yoshindo | Halarase | Halarase maruko | Halarase ohara | Harblasse | Herton | Inobase mita | Inobase tatumi | Letecrin | Lofreon | Neluos | Neoxy | Orivate sawai | Orivate yoshitomi | Oxybutynin HCL | Palnaxol | Pollakisu | Porabutin | Porabutin iwaki | Poratile | Postinin | Urgent | Volanta</span>;</li>
<li>
<span class="countryCode">(KE)</span> <span class="country">Kenya</span><span class="countrySeparator">: </span><span class="drugName">Oxinus</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Cystrin | Ditropan | Lailinel oros | Obutin | Obutine | Oksitin | Oxybutin | Oxynin | Oyrobin | Urinin | Urotinin | Utinin</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Apo-oxybutynin | Uripan</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Ditropan | Driptane</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Cystrin | Driptane | Lyrinel | Novitropan | Oxybutynin Accord | Oxybutynine Mylan</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Ditropan</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Cystrin | Driptane | Novitropan | Oxybutynin hydrochloride accord</span>;</li>
<li>
<span class="countryCode">(MA)</span> <span class="country">Morocco</span><span class="countrySeparator">: </span><span class="drugName">Ditropan | Oxybut | Urosta</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Inprax | Lyrinel | Nefryl | Tavor | Tavor cr</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Driptane | Voxytane</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Dridase | Kentera | Oxybutynine HCl | Oxybutynine Hcl A | Oxybutynine hcl cf | Oxybutynine Hcl Katwijk | Oxybutynine Hcl Merck | Oxybutynine Hcl PCH | Oxybutynine Hcl Sandoz | Oxybutynine hcl unichem</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Dridase | Kentera | Lyrinel XL | Oxybutynine biogaran</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Apo-oxybutynin | Oxybutynin | Oxytrol</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Oxibutinina clorhidrato | Reteven | Socliden | Uricont | Uritina | Uroxivan</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Driptane | Lyrinel</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Butyn | Cystrin | Oxitrin | Taivor</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Cystrin | Ditropan | Driptane | Kentera | Oxybutynin hydrochloride accord | Uralex</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Ditropan | Gelnique | Oxybutynin | Oxybutynin chloride | Oxybutynin chloride er | Oxytrol | Oxytrol for women</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Ditropan | Oxibutinina</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Socliden | Uroflax | Uroflax cr</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Ditropan | Driptane</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Driptane | Novitropan</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Apo-oxybutynin | Ditropan | Pms-oxybutynin</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Ditropan | Kentera | Oxybase | Oxybutinin accord | Oxybutynin 2care4 | Oxybutynin ebb | Oxybutynin mylan | Oxybutynin Stada</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Obutin</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Ditropan</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Ditropan | Eurin | Kentera | Uroxal</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Diatropan | Diutropan | Lyrinel</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Ditropan | Driptane | Oxybtan</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Kentera | Uropan</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Benlate | Blasec | Clonice | Ditropan | Newin | Oablok | Oubile | Oxbu | Oxipan | Oxyban | Oxybutynin | Oxypan | Oxytynin | Par Yih | Pintylin | Repinin | Urocon | Uronin</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Dream | Drimtan-Apo | Driptan | Sibutin</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Ditropan ud | Gradual | Incontin | Oxotine | Retebem | Socliden</span>;</li>
<li>
<span class="countryCode">(VE)</span> <span class="country">Venezuela, Bolivarian Republic of</span><span class="countrySeparator">: </span><span class="drugName">Reteven</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Ditropan | Lenditro | Lyrinel | Merck-oxybutynin | Micro-Oxybutynin | Oxyrest | Oxyspas | Rolab-oxybutynin | Urihexal</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-37139824">
<a name="37139824"></a>2023 American Geriatrics Society Beers Criteria Update Expert Panel. American Geriatrics Society 2023 updated AGS Beers Criteria for potentially inappropriate medication use in older adults. <i>J Am Geriatr Soc</i>. 2023;71(7):2052-2081. doi:10.1111/jgs.18372<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxybutynin-pediatric-drug-information/abstract-text/37139824/pubmed" id="37139824" target="_blank">37139824</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8835047">
<a name="8835047"></a>Adubofour KO, Kajiwara GT, Goldberg CM, King-Angell JL. Oxybutynin-induced heatstroke in an elderly patient. <i>Ann Pharmacother</i>. 1996;30(2):144-147. doi:10.1177/106002809603000207<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxybutynin-pediatric-drug-information/abstract-text/8835047/pubmed" id="8835047" target="_blank">8835047</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30237720">
<a name="30237720"></a>Alrawashdeh H, Madi L, Ahmed Elhada AH, Ahmed A, Serheed D. A case of probable oxybutynin-induced increase in liver enzymes. <i>Ther Clin Risk Manag</i>. 2018;14:1657-1660. doi:10.2147/TCRM.S169868<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxybutynin-pediatric-drug-information/abstract-text/30237720/pubmed" id="30237720" target="_blank">30237720</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9883225">
<a name="9883225"></a>Amark P, Eksborg S, Juneskans O, Bussman G, Palm C. Pharmacokinetics and effects of intravesical oxybutynin on the paediatric neurogenic bladder. <i>Br J Urol</i>. 1998;82(6):859-864. doi:10.1046/j.1464-410x.1998.00888.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxybutynin-pediatric-drug-information/abstract-text/9883225 /pubmed" id="9883225 " target="_blank">9883225 </a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9024461">
<a name="9024461"></a>American Academy of Pediatrics Committee on Drugs. "Inactive" ingredients in pharmaceutical products: update (subject review). <i>Pediatrics</i>. 1997;99(2):268-278. doi:10.1542/peds.99.2.268<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxybutynin-pediatric-drug-information/abstract-text/9024461/pubmed" id="9024461" target="_blank">9024461</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29600402">
<a name="29600402"></a>Andretta E, Landi LM, Cianfrocca M, Manassero A, Risi O, Artuso G. Bladder management during pregnancy in women with spinal-cord injury: an observational, multicenter study. <i>Int Urogynecol J</i>. 2019;30(2):293-300. doi:10.1007/s00192-018-3620-8<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxybutynin-pediatric-drug-information/abstract-text/29600402/pubmed" id="29600402" target="_blank">29600402</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Apotex.1">
<a name="Apotex.1"></a>Apo-oxybutynin (oxybutynin) [product monograph]. Weston, Ontario, Canada: Apotex Inc; January 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17333521">
<a name="17333521"></a>Armstrong RB, Dmochowski RR, Sand PK, Macdiarmid S. Safety and tolerability of extended-release oxybutynin once daily in urinary incontinence: combined results from two phase 4 controlled clinical trials. <i>Int Urol Nephrol</i>. 2007;39(4):1069-77. doi:10.1007/s11255-006-9157-7<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxybutynin-pediatric-drug-information/abstract-text/17333521/pubmed" id="17333521" target="_blank">17333521</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Beghin.1">
<a name="Beghin.1"></a>Beghin D, Vauzelle-Gardier C, Elefant E. Pregnancy outcome after in utero exposure to oxybutynin. <i>Reprod Toxicol</i>. 2016;60:177-178. https://doi.org/10.1016/j.reprotox.2016.03.018</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27373215">
<a name="27373215"></a>Berkenwald A, Pires J, Ellsworth P. Evaluating use of higher dose oxybutynin in combination with desmopressin for refractory nocturnal enuresis. <i>J Pediatr Urol</i>. 2016;12(4):220.e1-220.e2206. doi:10.1016/j.jpurol.2016.05.029<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxybutynin-pediatric-drug-information/abstract-text/27373215/pubmed" id="27373215" target="_blank">27373215</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18476934">
<a name="18476934"></a>Branson JA, Dale RC. Transient bilateral blindness and posterior reversible encephalopathy syndrome: a rare complication of enuresis treatment. <i>J Paediatr Child Health</i>. 2008;44(6):380-2. doi:10.1111/j.1440-1754.2008.01337.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxybutynin-pediatric-drug-information/abstract-text/18476934/pubmed" id="18476934" target="_blank">18476934</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9719281">
<a name="9719281"></a>Buyse G, Verpoorten C, Vereecken R, Casaer P. Intravesical application of a stable oxybutynin solution improves therapeutic compliance and acceptance in children with neurogenic bladder dysfunction. <i>J Urol</i>. 1998a;160(3 Pt 2):1084-1087. doi:10.1097/00005392-199809020-00031<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxybutynin-pediatric-drug-information/abstract-text/9719281/pubmed" id="9719281" target="_blank">9719281</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9720583">
<a name="9720583"></a>Buyse G, Waldeck K, Verpoorten C, Björk H, Casaer P, Andersson KE. Intravesical oxybutynin for neurogenic bladder dysfunction: less systemic side effects due to reduced first pass metabolism. <i>J Urol</i>. 1998b;160(3 Pt 1):892-896.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxybutynin-pediatric-drug-information/abstract-text/9720583 /pubmed" id="9720583 " target="_blank">9720583 </a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19683731">
<a name="19683731"></a>Cartwright PC, Coplen DE, Kogan BA, Volinn W, Finan E, Hoel G. Efficacy and safety of transdermal and oral oxybutynin in children with neurogenic detrusor overactivity. <i>J Urol</i>. 2009;182(4):1548-1554. doi:10.1016/j.juro.2009.06.058<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxybutynin-pediatric-drug-information/abstract-text/19683731/pubmed" id="19683731" target="_blank">19683731</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34176749">
<a name="34176749"></a>Casal-Beloy I, García-Novoa MA, García González M, Acea Nebril B, Somoza Argibay I. Transcutaneous sacral electrical stimulation versus oxibutynin for the treatment of overactive bladder in children. <i>J Pediatr Urol</i>. 2021;17(5):644.e1-644.e10. doi:10.1016/j.jpurol.2021.06.011<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxybutynin-pediatric-drug-information/abstract-text/34176749/pubmed" id="34176749" target="_blank">34176749</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22070184">
<a name="22070184"></a>Chancellor M, Boone T. Anticholinergics for overactive bladder therapy: central nervous system effects. <i>CNS Neurosci Ther</i>. 2012;18(2):167-74. doi:10.1111/j.1755-5949.2011.00248.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxybutynin-pediatric-drug-information/abstract-text/22070184/pubmed" id="22070184" target="_blank">22070184</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11394733">
<a name="11394733"></a>Chancellor MB, Appell RA, Sathyan G, Gupta SK. A comparison of the effects on saliva output of oxybutynin chloride and tolterodine tartrate. <i>Clin Ther</i>. 2001;23(5):753-60. doi:10.1016/s0149-2918(01)80024-2<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxybutynin-pediatric-drug-information/abstract-text/11394733/pubmed" id="11394733" target="_blank">11394733</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15970828">
<a name="15970828"></a>Chu FM, Dmochowski RR, Lama DJ, Anderson RU, Sand PK. Extended-release formulations of oxybutynin and tolterodine exhibit similar central nervous system tolerability profiles: a subanalysis of data from the OPERA trial. <i>Am J Obstet Gynecol</i>. 2005;192(6):1849-54; discussion 1854-5. doi:10.1016/j.ajog.2005.03.036<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxybutynin-pediatric-drug-information/abstract-text/15970828/pubmed" id="15970828" target="_blank">15970828</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23848044">
<a name="23848044"></a>Ciftci I, Arslan D, Peru H, Cimen D, Oran B, Gunduz M. Does oxybutynin hydrochloride cause arrhythmia in children with bladder dysfunction? <i>Med Arch</i>. 2013;67(3):202-4. doi:10.5455/medarh.2013.67.202-204<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxybutynin-pediatric-drug-information/abstract-text/23848044/pubmed" id="23848044" target="_blank">23848044</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16469019">
<a name="16469019"></a>Corcos J, Casey R, Patrick A, Andreou C, Miceli PC, Reiz JL, Harsanyi Z, Darke AC; Uromax Study Group. A double-blind randomized dose-response study comparing daily doses of 5, 10 and 15 mg controlled-release oxybutynin: balancing efficacy with severity of dry mouth. <i>BJU Int</i>. 2006;97(3):520-7. doi:10.1111/j.1464-410X.2005.06031.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxybutynin-pediatric-drug-information/abstract-text/16469019/pubmed" id="16469019" target="_blank">16469019</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11435842">
<a name="11435842"></a>Davila GW, Daugherty CA, Sanders SW; Transdermal Oxybutynin Study Group. A short-term, multicenter, randomized double-blind dose titration study of the efficacy and anticholinergic side effects of transdermal compared to immediate release oral oxybutynin treatment of patients with urge urinary incontinence. <i>J Urol</i>. 2001;166(1):140-5.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxybutynin-pediatric-drug-information/abstract-text/11435842/pubmed" id="11435842" target="_blank">11435842</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27122197">
<a name="27122197"></a>Del Boz J, Millán-Cayetano JF, Blázquez-Sánchez N, de Troya M. Individualized dosing of oral oxybutynin for the treatment of primary focal hyperhidrosis in children and teenagers. <i>Pediatr Dermatol</i>. 2016;33(3):327-331. doi:10.1111/pde.12857<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxybutynin-pediatric-drug-information/abstract-text/27122197/pubmed" id="27122197" target="_blank">27122197</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-DitropanXL.2019.09">
<a name="DitropanXL.2019.09"></a>Ditropan XL (oxybutynin) [prescribing information]. Titusville, NJ: Janssen Pharmaceuticals Inc; received April 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18439051">
<a name="18439051"></a>D'Souza AO, Smith MJ, Miller LA, Doyle J, Ariely R. Persistence, adherence, and switch rates among extended-release and immediate-release overactive bladder medications in a regional managed care plan. <i>J Manag Care Pharm</i>. 2008;14(3):291-301. doi:10.18553/jmcp.2008.14.3.291<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxybutynin-pediatric-drug-information/abstract-text/18439051/pubmed" id="18439051" target="_blank">18439051</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Expert.DOR">
<a name="Expert.DOR"></a>Expert opinion. Senior Renal Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11350411">
<a name="11350411"></a>Ferrara P, D'Aleo CM, Tarquini E, Salvatore S, Salvaggio E. Side-effects of oral or intravesical oxybutynin chloride in children with spina bifida. <i>BJU Int</i>. 2001;87(7):674-678. doi:10.1046/j.1464-410x.2001.02152.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxybutynin-pediatric-drug-information/abstract-text/11350411 /pubmed" id="11350411 " target="_blank">11350411 </a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Gelnique.2019.03">
<a name="Gelnique.2019.03"></a>Gelnique (oxybutynin) gel [prescribing information]. Madison, NJ: Allergan USA, Inc; March 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Gelnique.2017.03">
<a name="Gelnique.2017.03"></a>Gelnique (oxybutynin) [product monograph]. Markham, Ontario, Canada: Allergan Pharma; March 2017.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23028229">
<a name="23028229"></a>Ghaleiha A, Jahangard L, Sherafat Z, et al. Oxybutynin reduces sweating in depressed patients treated with sertraline: a double-blind, placebo-controlled, clinical study. <i>Neuropsychiatr Dis Treat</i>. 2012;8:407-12. doi:10.2147/NDT.S36329<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxybutynin-pediatric-drug-information/abstract-text/23028229/pubmed" id="23028229" target="_blank">23028229</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24477421">
<a name="24477421"></a>Gleason JM, Daniels C, Williams K, et al. Single center experience with oxybutynin transdermal system (patch) for management of symptoms related to non-neuropathic overactive bladder in children: an attractive, well tolerated alternative form of administration. <i>J Pediatr Urol</i>. 2014;10(4):753-757. doi:10.1016/j.jpurol.2013.12.017<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxybutynin-pediatric-drug-information/abstract-text/24477421 /pubmed" id="24477421 " target="_blank">24477421 </a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Gormley.2019">
<a name="Gormley.2019"></a>Gormley EA, Lightner DJ, Burgio KL, et al. Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA/SUFU guideline. American Urological Association website. https://www.auanet.org/guidelines/overactive-bladder-(oab)-guideline#x14217. Published 2012. Updated 2019. Accessed July 2, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18786150">
<a name="18786150"></a>Götz AK, Reinhold SW, Szecsey A, Banas B, Krämer BK. Severe anticholinergic drug-induced delirium in a young adult after renal transplantation. <i>Transpl Int</i>. 2009;22(2):249-50. doi:10.1111/j.1432-2277.2008.00759.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxybutynin-pediatric-drug-information/abstract-text/18786150/pubmed" id="18786150" target="_blank">18786150</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33931318">
<a name="33931318"></a>Gözüküçük A, Kılıç M, Çakıroğlu B. Desmopressin versus desmopressin + oxybutynin in the treatment of children with nocturnal enuresis. <i>J Pediatr Urol</i>. 2021;17(4):451.e1-451.e6. doi:10.1016/j.jpurol.2021.04.001<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxybutynin-pediatric-drug-information/abstract-text/33931318/pubmed" id="33931318" target="_blank">33931318</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18639290">
<a name="18639290"></a>Guerra LA, Moher D, Sampson M, Barrowman N, Pike J, Leonard M. Intravesical oxybutynin for children with poorly compliant neurogenic bladder: a systematic review. <i>J Urol</i>. 2008;180(3):1091-1097. doi:10.1016/j.juro.2008.05.056<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxybutynin-pediatric-drug-information/abstract-text/18639290/pubmed" id="18639290" target="_blank">18639290</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17163294">
<a name="17163294"></a>Gulsun M, Pinar M, Sabanci U. Psychotic disorder induced by oxybutynin: Presentation of two cases. <i>Clin Drug Investig</i>. 2006;26(10):603-6. doi:10.2165/00044011-200626100-00007<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxybutynin-pediatric-drug-information/abstract-text/17163294/pubmed" id="17163294" target="_blank">17163294</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30087808">
<a name="30087808"></a>Haddad A, Arwani M, Sabbagh O. A novel association between oxybutynin use and bilateral acute angle closure glaucoma: a case report and literature review. <i>Cureus</i>. 2018;10(6):e2732. doi:10.7759/cureus.2732<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxybutynin-pediatric-drug-information/abstract-text/30087808/pubmed" id="30087808" target="_blank">30087808</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10822396">
<a name="10822396"></a>Haferkamp A, Staehler G, Gerner HJ, Dörsam J. Dosage escalation of intravesical oxybutynin in the treatment of neurogenic bladder patients. <i>Spinal Cord</i>. 2000;38(4):250-254. doi:10.1038/sj.sc.3100995<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxybutynin-pediatric-drug-information/abstract-text/10822396/pubmed" id="10822396" target="_blank">10822396</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33052696">
<a name="33052696"></a>Harley JAT. Oxybutynin for methadone-induced sweating in pregnancy. <i>Australas Psychiatry</i>. 2020:1039856220965055. doi:10.1177/1039856220965055<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxybutynin-pediatric-drug-information/abstract-text/33052696/pubmed" id="33052696" target="_blank">33052696</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8824696">
<a name="8824696"></a>Hussain RM, Hartigan-Go K, Thomas SH, Ford GA. Effect of oxybutynin on the QTc interval in elderly patients with urinary incontinence. <i>Br J Clin Pharmacol</i>. 1996;41(1):73-5. doi:10.1111/j.1365-2125.1996.tb00161.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxybutynin-pediatric-drug-information/abstract-text/8824696/pubmed" id="8824696" target="_blank">8824696</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26166994">
<a name="26166994"></a>Jain D, Dhua A, Ravisankar V, Chellam L, Joshi M. Acute angle closure glaucoma after hypospadias surgery: a vision-threatening complication of oxybutynin. <i>J Indian Assoc Pediatr Surg</i>. 2015;20(3):161-2. doi:10.4103/0971-9261.154662<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxybutynin-pediatric-drug-information/abstract-text/26166994/pubmed" id="26166994" target="_blank">26166994</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9434659">
<a name="9434659"></a>Katz IR, Sands LP, Bilker W, et al. Identification of medications that cause cognitive impairment in older people: the case of oxybutynin chloride. <i>J Am Geriatr Soc. </i>1998;46(1):8-13. doi:10.1111/j.1532-5415.1998.tb01006.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxybutynin-pediatric-drug-information/abstract-text/9434659/pubmed" id="9434659" target="_blank">9434659</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18699842">
<a name="18699842"></a>Kay GG, Ebinger U. Preserving cognitive function for patients with overactive bladder: evidence for a differential effect with darifenacin. <i>Int J Clin Pract</i>. 2008;62(11):1792-800. doi:10.1111/j.1742-1241.2008.01849.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxybutynin-pediatric-drug-information/abstract-text/18699842/pubmed" id="18699842" target="_blank">18699842</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32968391">
<a name="32968391"></a>Kazi A, Moorani KN, Zehra S, Zaidi IH. Comparative response of desmopressin versus combination therapy (desmopressin + oxybutynin) in children with nocturnal enuresis. <i>Pak J Med Sci</i>. 2020;36(6):1263-1269. doi:10.12669/pjms.36.6.1957<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxybutynin-pediatric-drug-information/abstract-text/32968391/pubmed" id="32968391" target="_blank">32968391</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20428289">
<a name="20428289"></a>Kennelly MJ. A comparative review of oxybutynin chloride formulations: pharmacokinetics and therapeutic efficacy in overactive bladder. <i>Rev Urol</i>. 2010;12(1):12-19.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxybutynin-pediatric-drug-information/abstract-text/20428289 /pubmed" id="20428289 " target="_blank">20428289 </a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28712052">
<a name="28712052"></a>Kroll P. Pharmacotherapy for pediatric neurogenic bladder. <i>Paediatr Drugs</i>. 2017;19(5):463-478. doi:10.1007/s40272-017-0249-x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxybutynin-pediatric-drug-information/abstract-text/28712052/pubmed" id="28712052" target="_blank">28712052</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18410326">
<a name="18410326"></a>Lackner TE, Wyman JF, McCarthy TC, Monigold M, Davey C. Randomized, placebo-controlled trial of the cognitive effect, safety, and tolerability of oral extended-release oxybutynin in cognitively impaired nursing home residents with urge urinary incontinence. <i>J Am Geriatr Soc</i>. 2008;56(5):862-70. doi:10.1111/j.1532-5415.2008.01680.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxybutynin-pediatric-drug-information/abstract-text/18410326/pubmed" id="18410326" target="_blank">18410326</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32115375">
<a name="32115375"></a>Lee AS, Viseshsindh W, Long CJ, et al. How early is early? Effect of oxybutynin on bladder dynamics within the first year of life in patients with spina bifida. <i>J Pediatr Urol</i>. 2020;16(2):168.e1-168.e6. doi:10.1016/j.jpurol.2019.12.008<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxybutynin-pediatric-drug-information/abstract-text/32115375/pubmed" id="32115375" target="_blank">32115375</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34384237">
<a name="34384237"></a>Lerner LB, McVary KT, Barry MJ, et al. Management of lower urinary tract symptoms attributed to benign prostatic hyperplasia: AUA guideline part I, initial work-up and medical management. <i>J Urol</i>. 2021;206(4):806-817. doi:10.1097/JU.0000000000002183<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxybutynin-pediatric-drug-information/abstract-text/34384237/pubmed" id="34384237" target="_blank">34384237</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Lukacz.2019">
<a name="Lukacz.2019"></a>Lukacz ES. Urgency urinary incontinence/overactive bladder (OAB) in females: Treatment. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed May 24, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20596778">
<a name="20596778"></a>Meek PD, Evang SD, Tadrous M, Roux-Lirange D, Triller DM, Gumustop B. Overactive bladder drugs and constipation: a meta-analysis of randomized, placebo-controlled trials. <i>Dig Dis Sci</i>. 2011;56(1):7-18. doi:10.1007/s10620-010-1313-3<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxybutynin-pediatric-drug-information/abstract-text/20596778/pubmed" id="20596778" target="_blank">20596778</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27029500">
<a name="27029500"></a>Millán-Cayetano JF, Del Boz J, Rivas-Ruiz F, Blázquez-Sánchez N, Hernández Ibáñez C, de Troya-Martín M. Oral oxybutynin for the treatment of hyperhidrosis: outcomes after one-year follow-up. <i>Australas J Dermatol</i>. 2017;58(2):e31-e35. doi:10.1111/ajd.12473<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxybutynin-pediatric-drug-information/abstract-text/27029500/pubmed" id="27029500" target="_blank">27029500</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Nelson.2019">
<a name="Nelson.2019"></a>Nelson LS. Initial evaluation of the patient: vital signs and toxic syndromes. In: Nelson LS, Hoffman RS, Howland MA, Lewin NA, Goldfrank LR, Smith SW, eds. <i>Goldfrank's Toxicologic Emergencies</i>. 11th ed. McGraw-Hill; 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35587029">
<a name="35587029"></a>Nishtala PS, Chyou TY. Risk of delirium associated with antimuscarinics in older adults: a case-time-control study. <i>Pharmacoepidemiol Drug Saf</i>. 2022;31(8):883-891. doi:10.1002/pds.5480<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxybutynin-pediatric-drug-information/abstract-text/35587029/pubmed" id="35587029" target="_blank">35587029</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20211824">
<a name="20211824"></a>Nye AM, Clinard VB, Barnes CL. Medication nonadherence secondary to drug-induced memory loss. <i>Consult Pharm</i>. 2010;25(2):117-21. doi:10.4140/TCP.n.2010.117<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxybutynin-pediatric-drug-information/abstract-text/20211824/pubmed" id="20211824" target="_blank">20211824</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Lannett.1">
<a name="Lannett.1"></a>Oxybutynin extended release tablet (oxybutynin) [prescribing information]. Philadelphia, PA: Lannett Company, Inc; April 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Lannett.2">
<a name="Lannett.2"></a>Oxybutynin syrup (oxybutynin) [prescribing information]. Philadelphia, PA: Lannett Company, Inc; February 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Strides.1">
<a name="Strides.1"></a>Oxybutynin tablet (oxybutynin) [prescribing information]. East Brunswick, NJ: Strides Pharma Inc; November 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Oxytrol.2015.07">
<a name="Oxytrol.2015.07"></a>Oxytrol (oxybutynin) transdermal patch [prescribing information]. Irvien, CA: Allergan USA, Inc; October 2017.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Oxytrol.2018.03">
<a name="Oxytrol.2018.03"></a>Oxytrol (oxybutynin) [product monograph]. Markham, Ontario, Canada: Allergan Pharma; March 2018.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Oxytrol.2020.05">
<a name="Oxytrol.2020.05"></a>Oxytrol for Women (oxybutynin) transdermal system [prescribing information]. Madison, NJ: Allergan USA, Inc; received May 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18602302">
<a name="18602302"></a>Pemberton MN, Yar R, Sloan P. Fixed drug eruption to oxybutynin. <i>Oral Surg Oral Med Oral Pathol Oral Radiol Endod</i>. 2008;106(3):e19-21. doi:10.1016/j.tripleo.2008.05.004<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxybutynin-pediatric-drug-information/abstract-text/18602302/pubmed" id="18602302" target="_blank">18602302</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25222388">
<a name="25222388"></a>Qaseem A, Dallas P, Forciea MA, et al; Clinical Guidelines Committee of the American College of Physicians. Nonsurgical management of urinary incontinence in women: a clinical practice guideline from the American College of Physicians [published correction appears in <i>Ann Intern Med</i>. 2014;161(10):764]. <i>Ann Intern Med.</i> 2014;161(6):429-440. doi:10.7326/M13-2410.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxybutynin-pediatric-drug-information/abstract-text/25222388/pubmed" id="25222388" target="_blank">25222388</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22532368">
<a name="22532368"></a>Rawashdeh YF, Austin P, Siggaard C, et al. International Children's Continence Society's recommendations for therapeutic intervention in congenital neuropathic bladder and bowel dysfunction in children. <i>Neurourol UrodynR</i>. 2012;31(5):615-620. doi:10.1002/nau.22248<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxybutynin-pediatric-drug-information/abstract-text/22532368/pubmed" id="22532368" target="_blank">22532368</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Manu.1">
<a name="Manu.1"></a>Refer to manufacturer's labeling.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26114588">
<a name="26114588"></a>Schollhammer M, Brenaut E, Menard-Andivot N, et al. Oxybutynin as a treatment for generalized hyperhidrosis: a randomized, placebo-controlled trial. <i>Br J Dermatol</i>. 2015;173(5):1163-1168. doi:10.1111/bjd.13973.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxybutynin-pediatric-drug-information/abstract-text/26114588/pubmed" id="26114588" target="_blank">26114588</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19188870">
<a name="19188870"></a>Shehab N, Lewis CL, Streetman DD, Donn SM. Exposure to the pharmaceutical excipients benzyl alcohol and propylene glycol among critically ill neonates. <i>Pediatr Crit Care Med</i>. 2009;10(2):256-259. doi:10.1097/PCC.0b013e31819a383c<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxybutynin-pediatric-drug-information/abstract-text/19188870/pubmed" id="19188870" target="_blank">19188870</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Smith.2020">
<a name="Smith.2020"></a>Smith CC, Pariser D. Primary focal hyperhidrosis. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed May 9, 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16483863">
<a name="16483863"></a>Staskin DR, MacDiarmid SA. Using anticholinergics to treat overactive bladder: the issue of treatment tolerability. <i>Am J Med</i>. 2006;119(3 Suppl 1):9-15. doi:10.1016/j.amjmed.2005.12.011<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxybutynin-pediatric-drug-information/abstract-text/16483863/pubmed" id="16483863" target="_blank">16483863</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31724222">
<a name="31724222"></a>Stein R, Bogaert G, Dogan HS, et al. EAU/ESPU guidelines on the management of neurogenic bladder in children and adolescent part I diagnostics and conservative treatment. <i>Neurourol Urodyn</i>. 2020;39(1):45-57. doi:10.1002/nau.24211<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxybutynin-pediatric-drug-information/abstract-text/31724222/pubmed" id="31724222" target="_blank">31724222</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-37160401">
<a name="37160401"></a>Stoniute A, Madhuvrata P, Still M, Barron-Millar E, Nabi G, Omar MI. Oral anticholinergic drugs versus placebo or no treatment for managing overactive bladder syndrome in adults. <i>Cochrane Database Syst Rev</i>. 2023;5(5):CD003781. doi:10.1002/14651858.CD003781.pub3<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxybutynin-pediatric-drug-information/abstract-text/37160401/pubmed" id="37160401" target="_blank">37160401</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35536677">
<a name="35536677"></a>Sze C, Drangsholt S, Stoddard MD, et al. Adverse events for overactive bladder medications from a public federal database. <i>Female Pelvic Med Reconstr Surg</i>. 2022;28(7):429-435. doi:10.1097/SPV.0000000000001190<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxybutynin-pediatric-drug-information/abstract-text/35536677/pubmed" id="35536677" target="_blank">35536677</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31117096">
<a name="31117096"></a>van den Heijkant M, De Coster K, Jansen K, Bogaert G. Can oral fesoterodine be an alternative for intravesical oxybutynin instillations in children with neuropathic bladder dysfunction? <i>Urol Int</i>. 2019;103(2):202-210. doi:10.1159/000499757<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxybutynin-pediatric-drug-information/abstract-text/31117096/pubmed" id="31117096" target="_blank">31117096</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23332882">
<a name="23332882"></a>Wagg A, Dale M, Tretter R, Stow B, Compion G. Randomised, multicentre, placebo-controlled, double-blind crossover study investigating the effect of solifenacin and oxybutynin in elderly people with mild cognitive impairment: the SENIOR study. <i>Eur Urol</i>. 2013;64(1):74-81. doi:10.1016/j.eururo.2013.01.002<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxybutynin-pediatric-drug-information/abstract-text/23332882/pubmed" id="23332882" target="_blank">23332882</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22341836">
<a name="22341836"></a>Wolosker N, de Campos JR, Kauffman P, et al. A randomized placebo-controlled trial of oxybutynin for the initial treatment of palmar and axillary hyperhidrosis. <i>J Vasc Surg</i>. 2012;55(6):1696-1700. doi:10.1016/j.jvs.2011.12.039.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxybutynin-pediatric-drug-information/abstract-text/22341836/pubmed" id="22341836" target="_blank">22341836</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23627681">
<a name="23627681"></a>Wolosker N, Schvartsman C, Krutman M, et al. Efficacy and quality of life outcomes of oxybutynin for treating palmar hyperhidrosis in children younger than 14 years old. <i>Pediatr Dermatol</i>. 2014a;31(1):48-53. doi:10.1111/pde.12142<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxybutynin-pediatric-drug-information/abstract-text/23627681/pubmed" id="23627681" target="_blank">23627681</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25490865">
<a name="25490865"></a>Wolosker N, Teivelis MP, Krutman M, et al. Long-term efficacy of oxybutynin for palmar and plantar hyperhidrosis in children younger than 14 years. <i>Pediatr Dermatol</i>. 2014b;32(5):663-667. doi:10.1111/pde.12385<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxybutynin-pediatric-drug-information/abstract-text/25490865/pubmed" id="25490865" target="_blank">25490865</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 12665 Version 538.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
